Methylcitric Acid

If you or your child has had unexplained episodes of severe acidosis, lethargy, vomiting, or developmental delay, this is one of the tests that can finally name what is happening. Methylcitric acid in urine reveals whether a specific inherited block in protein metabolism is quietly poisoning cells from the inside.

It is most often ordered when doctors suspect an inborn error of metabolism in a newborn, child, or rarely an adult with a late-onset variant. For people already living with one of these conditions, this number tracks how well treatment is keeping the underlying chemistry under control.

What This Molecule Actually Is

MCA (methylcitric acid) is a small molecule formed when a metabolic building block called propionyl-CoA piles up inside cells. Normally, cells combine acetyl-CoA with another molecule to make citric acid, which feeds the cell's main energy-producing cycle. When propionyl-CoA accumulates, it gets substituted in by mistake, producing methylcitric acid instead. The body cannot use this substitute properly, and it spills into the blood and urine.

The pile-up of propionyl-CoA happens in inherited conditions called PA (propionic acidemia) and MMA (methylmalonic acidemia). In PA, the enzyme that processes propionyl-CoA is missing or broken. In MMA, a different enzyme one step further down the pathway is the problem. Both lead to the same downstream traffic jam, and both produce elevated methylcitric acid in urine.

What High Levels Mean

Methylcitric acid is very low in healthy people. In people with PA or MMA, levels run far above what is seen in healthy individuals. A dried blood spot follow-up study found elevated methylcitric acid in 100% of PA patients and in 95.2% of isolated MMA patients on treatment.

Levels also help separate genetic disease from acquired causes. A newborn screening program of 258,637 babies found methylcitric acid was markedly elevated in roughly half of genetic vitamin B12-related disorders but in only 5% of cases caused by simple acquired B12 deficiency. In confirmed PA, the marker was described as "always very high."

What This Means for Disease Severity

Higher methylcitric acid generally tracks with more severe disease. In a study of 22 patients with PA or MMA, higher plasma methylcitric acid correlated with greater overall disease burden, more long-term complications, worse kidney function (lower filtration rate in MMA), and higher ammonia, glycine, lysine, and propionylcarnitine levels.

In MMA specifically, a study of 20 patients found that larger and more frequent swings in toxic organic acid levels, including methylcitric acid, were linked to worse neurodevelopmental outcomes and lower IQ scores. Milder genetic variants tend to show lower urinary methylcitric acid and better long-term outcomes. For example, a study of 30 Chinese MMA patients with a rare MMUT gene mutation found milder biochemical abnormalities, easier metabolic control, and lower morbidity than classic severe MMA.

Kidney and Brain Risks

In MMA, higher methylcitric acid associates with worse kidney filtration. The same pile-up of toxic metabolites that produces methylcitric acid can damage the small filtering units of the kidney over time. This is why MMA care includes regular kidney monitoring, not just metabolic checks.

For the brain, methylcitric acid itself appears to interfere with how brain cells use energy. Patients with higher and more variable levels show more cognitive impairment, demyelination, and developmental delay. This is part of why aggressive metabolic control matters in these conditions, even when a child appears clinically stable.

What Lowering Levels Looks Like

The clearest evidence that a treatment is changing the underlying biology, not just the lab number, comes from organ transplantation. In a study of 39 children with PA who received liver transplants, urinary methylcitric acid fell substantially within 6 months. A related acylcarnitine ratio (C3-to-C2) also dropped significantly. In the combined PA and MMA study above, all transplanted patients had significant reductions in plasma methylcitric acid, with the largest drops in MMA patients who received both a liver and kidney.

Dietary protein restriction, carnitine, ammonia scavengers, and vitamin B12 in responsive forms of MMA are the standard medical pillars of care. These approaches reduce decompensation events and complications, though their precise effects on urinary methylcitric acid levels are less consistently quantified in the available research.

Why One Reading Is Not Enough

Methylcitric acid varies day to day in people with PA and MMA, especially with illness, growth, and changes in diet. A single reading captures one moment in a system that swings substantially over hours and days. The research on neurodevelopment specifically shows that swings in toxic acid levels, not just average levels, predict outcomes.

For someone with confirmed PA or MMA, the most useful pattern is regular tracking alongside companion markers. A reasonable cadence is at least every few months in stable disease, with extra testing during illness, growth spurts, or any change in treatment. After a major intervention such as transplant or starting a new therapy, retesting within 3 to 6 months captures whether the metabolic chemistry is actually shifting.

When Results Can Be Misleading

A few practical points can affect how a single result reads:

• Hydration and urine concentration: very dilute or very concentrated urine can shift the apparent number. Most labs correct for this by reporting results relative to creatinine, another molecule excreted at a steady rate.
• Acute illness or fasting: infections, vomiting, and not eating can push the underlying metabolism into a crisis state, sending methylcitric acid sharply higher. A reading taken during acute illness reflects the crisis, not baseline control.
• Recent diet shifts: a sudden large protein meal or relaxation of dietary restrictions in someone with PA or MMA can transiently raise levels. Standardizing the testing context matters more than chasing a single result.
• Specimen handling: organic acid analysis is technically demanding. Samples that sit at room temperature too long or are not properly preserved can give unreliable readings.

How This Test Fits With Others

Methylcitric acid is rarely interpreted alone. In a typical workup for suspected PA or MMA, doctors look at several markers together to map exactly where the metabolic block sits.

What this means for you: a normal methylcitric acid in someone with vague symptoms does not rule out every metabolic problem, and a high level does not by itself name which disorder is present. The pattern across these markers, plus genetic testing, is what builds the diagnosis.

What an Unexpected Result Should Prompt

If you ordered this test because of unexplained symptoms and the result is elevated, the next step is not to wait. Pair it with a urine organic acid profile, plasma acylcarnitines, ammonia, and homocysteine to clarify the picture. A genetic and metabolic specialist should be involved early. Confirmatory genetic testing for the MMUT, PCCA, PCCB, or related genes is usually the path to a definitive answer.

If you already have a PA or MMA diagnosis and the level is trending up, that is a signal to revisit dietary protein intake, check carnitine status, look for infections or other stressors, and consider whether current therapy needs adjustment. A rising methylcitric acid trend over months, especially paired with falling kidney function or worsening neurological symptoms, is the kind of pattern that prompts conversations about advanced options including transplantation.

A Note on Use in Healthy Adults

There is no current research supporting urinary methylcitric acid as a preventive screen in apparently healthy adults. Its value sits squarely in three settings: confirming or ruling out inherited propionate metabolism disorders, monitoring people already diagnosed, and second-tier newborn screening. For adults without symptoms or a relevant family history, standard metabolic panels remain the right starting point.